
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd. has demonstrated substantial growth potential, as evidenced by a 43% year-over-year increase in remaining performance obligations, totaling approximately $70 million. The company’s shipment of 95 Deep TMS systems in the fourth quarter reflects a notable 27% rise, bolstering its revenue projections with a forecasted increase from $65.6 million to $66.8 million for full-year 2026 and a new estimate of $81.2 million for 2027. Additionally, the approval of Neurolief's ProlivRx device enhances BrainsWay's strategic position and supports a favorable medium- to long-term financial outlook, further solidifying the stock's growth narrative.
Bears say
BrainsWay Ltd faces significant challenges that contribute to a negative outlook on its stock performance. Key risks include a slower than projected uptake of its Deep TMS systems, difficulties in expanding reimbursement and market access, and the potential inability to advance its treatment for additional indications. Additionally, there exists a concern regarding long-term dilution risk, which could further impact shareholder value and overall financial stability.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares